APA

Sarobe P., Pendleton C. D., Akatsuka T., Lau D., Engelhard V. H., Feinstone S. M. & Berzofsky J. A. (19981013). Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. : The Journal of clinical investigation.

Chicago

Sarobe P, Pendleton C D, Akatsuka T, Lau D, Engelhard V H, Feinstone S M and Berzofsky J A. 19981013. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. : The Journal of clinical investigation.

Harvard

Sarobe P., Pendleton C. D., Akatsuka T., Lau D., Engelhard V. H., Feinstone S. M. and Berzofsky J. A. (19981013). Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. : The Journal of clinical investigation.

MLA

Sarobe P, Pendleton C D, Akatsuka T, Lau D, Engelhard V H, Feinstone S M and Berzofsky J A. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. : The Journal of clinical investigation. 19981013.